NRG Oncology

06/09/2026

Announcing the Protocol Support Committee (PSC) – Continuing Educational Sessions! The CE Session for Nurse/CRAs on Thursday morning will be held virtually & in-person. The monthly “Discuss With Us” session for July is being held as a live session in Denver where Patient Advocacy will be discussed! The afternoon in-person roundtable sessions will cover a variety of topics, including discussions focusing on specific NRG disease-site studies, Best Practices for Organizing Your Workday, and more!

06/09/2026

There's still time to REGISTER for our NRG-GU015 "ARCHER" site webinar discussing the study assessments for the trial studying shorter duration RT for patients receiving chemotherapy for bladder cancer. This webinar will be TODAY at 1PM ET. Register at bit.ly/NRG-ARCHER-RT

06/08/2026

NRG Oncology Weekly Broadcast for June 8, 2026: https://conta.cc/4dWd8CE

06/06/2026

Dr. Eskander discusses the overall survival analysis and examination of subsequent therapy in patients with endometrial cancer treated with pembrolizumab plus carboplatin/paclitaxel as compared to carboplatin/paclitaxel plus placebo in the NRG-GY018 trial during . https://ascopost.com/videos/asco-2026/ramez-n-eskander-on-endometrial-cancer-pembrolizumab-plus-carboplatinpaclitaxel/

Ramez N. Eskander, MD, on Endometrial Cancer: Pembrolizumab Plus Carboplatin/Paclitaxel ASCO 2026 Advertisement Ramez N. Eskander, MD, of UC San Diego Moores Cancer Center, presents an updated overall survival analysis and examination of subsequent therapy in patients with endometrial cancer treated...

06/05/2026

The June issue of FORTE Fridays is now available. This month, we're highlighting the upcoming Amendment 9 updates, consent withdrawal process, and the FORTE Workshop at . Read it here ➡️https://conta.cc/4fSiU9x The FORTE Study

06/04/2026

June is . Endometrial cancer is the most common type of . Currently enrolling patients, NRG-GY035 is a Phase III study testing the addition of antiangiogenic drug to chemotherapy combined with immunotherapy for pMMR, TP53 mutated . Learn more: https://ow.ly/LY5650Z7J0K

06/03/2026

June is Cancer Survivors Month, a time to celebrate the strength, resilience, and courage of the millions of cancer survivors whose journeys inspire hope every day.

Survivorship is more than a milestone. It is a lifelong journey that highlights the importance of continued research, supportive care, and access to innovative treatments that help patients live longer and better lives.

This month, we honor survivors, recognize their unique experiences, and reaffirm our commitment to advancing cancer research that improves outcomes for future generations.

06/02/2026

Premenopausal patients w/ER-positive/HER2-negative who remain at high risk for recurrence may benefit from intensified systemic therapy strategies. Yesterday at , Dr. Mamounas discussed the NRG-BR009 OFSET study that is evaluating whether adding chemotherapy to ovarian function suppression + endocrine therapy can improve outcomes compared to standard hormonal treatment alone.

06/02/2026

1 WEEK AWAY - REGISTER for our NRG-GU015 "ARCHER" site webinar discussing the study assessments for the trial studying shorter duration RT for patients receiving chemotherapy for bladder cancer. This webinar will be June 9th at 1:00PM ET. Register at bit.ly/NRG-ARCHER-RT

06/01/2026

Currently enrolling patients, the NRG-BR009/OFSET study is evaluating whether adding chemotherapy to ovarian function suppression + endocrine therapy can improve outcomes compared to standard hormonal treatment alone. Dr. Terry Mamounas discusses the trial during a poster session at this afternoon.